HK110093A - Phenyl carbamate - Google Patents

Phenyl carbamate Download PDF

Info

Publication number
HK110093A
HK110093A HK1100/93A HK110093A HK110093A HK 110093 A HK110093 A HK 110093A HK 1100/93 A HK1100/93 A HK 1100/93A HK 110093 A HK110093 A HK 110093A HK 110093 A HK110093 A HK 110093A
Authority
HK
Hong Kong
Prior art keywords
phenyl carbamate
ethyl
phenylncarbamate
dimethylamino
pharmaceutical
Prior art date
Application number
HK1100/93A
Other languages
English (en)
Inventor
Enz Albert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6322236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK110093(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK110093A publication Critical patent/HK110093A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK1100/93A 1987-03-04 1993-10-21 Phenyl carbamate HK110093A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3706914 1987-03-04

Publications (1)

Publication Number Publication Date
HK110093A true HK110093A (en) 1993-10-29

Family

ID=6322236

Family Applications (1)

Application Number Title Priority Date Filing Date
HK1100/93A HK110093A (en) 1987-03-04 1993-10-21 Phenyl carbamate

Country Status (29)

Country Link
US (1) US5602176A (cs)
JP (3) JP2625478B2 (cs)
KR (1) KR0133686B1 (cs)
AT (1) AT394190B (cs)
AU (1) AU618949B2 (cs)
BE (1) BE1001467A3 (cs)
CA (1) CA1307003C (cs)
CH (1) CH675720A5 (cs)
CS (1) CS411091A3 (cs)
CY (1) CY1735A (cs)
DK (1) DK175762B1 (cs)
ES (1) ES2010527A6 (cs)
FI (1) FI89165C (cs)
FR (1) FR2611707B1 (cs)
GB (1) GB2203040C (cs)
GR (1) GR1000023B (cs)
HK (1) HK110093A (cs)
HU (1) HU201906B (cs)
IE (1) IE61714B1 (cs)
IL (1) IL85609A (cs)
IT (1) IT1219853B (cs)
LU (2) LU87150A1 (cs)
MY (1) MY103225A (cs)
NL (1) NL195004C (cs)
NZ (1) NZ223714A (cs)
PT (1) PT86875B (cs)
SA (1) SA93140384B1 (cs)
SE (1) SE8800731A0 (cs)
ZA (1) ZA881584B (cs)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU201906B (en) * 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
JP3598116B2 (ja) * 1994-04-15 2004-12-08 雅臣 伊豫 遅発性ジスキネジアの治療用医薬組成物とその利用
ES2241064T3 (es) 1996-12-18 2005-10-16 Teva Pharmaceutical Industries, Ltd. Derivados de aminoindano.
AU5620998A (en) * 1996-12-18 1998-07-15 Technion Research & Development Foundation Ltd. Phenylethylamine derivatives
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
GB9800526D0 (en) 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US6316023B1 (en) * 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
BR9914251A (pt) 1998-10-01 2001-06-19 Novartis Ag Formulações orais de liberação sustentada
US20040209849A1 (en) * 1998-11-27 2004-10-21 Sanochemia Pharmazeutika Aktiengesellschaft Use of effectors of the central cholinergic nervous system for treatment of delirium
CA2354035A1 (en) * 1998-12-11 2000-06-15 Bonnie Davis Use of acetylcholinesterase inhibitors on the modulation of the hypothalamic-pituitary-gonadal axis
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
US6534541B1 (en) 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders
WO2001078721A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Aβ42 LOWERING AGENTS
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
US20040087658A1 (en) * 2002-10-24 2004-05-06 Hans-Joerg Moebius Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
CZ293014B6 (cs) 2002-10-24 2004-01-14 Léčiva, A.S. Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
EP1651195A4 (en) * 2003-07-11 2007-10-03 Myriad Genetics Inc PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
CA2543322A1 (en) * 2003-10-21 2005-05-12 Sention, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
GB2409453A (en) * 2003-12-24 2005-06-29 Generics Process for the preparation of aminoalkyl phenylcarbamates
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
KR20070004036A (ko) * 2004-04-29 2007-01-05 키스톤 리테이닝 월 시스템스, 아이엔씨 벽, 옹벽 및 그 외 유사한 것을 위한 베니어
EP1779867A4 (en) * 2004-07-01 2009-12-02 Eisai R&D Man Co Ltd MEANS FOR PROMOTING NERVE REVENERATION
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006048720A1 (en) * 2004-11-08 2006-05-11 Emcure Pharmaceuticals Limited An efficient method for preparation of (s)-3-[(1-dimethyl amino)ethyl]-phenyl-n-ethyl-n-methyl-carbamate
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
ES2267399B1 (es) 2005-08-04 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de carbamatos de fenilo.
EP2111901B1 (en) 2005-09-15 2012-02-01 Sony Computer Entertainment Inc. Obtaining input for controlling execution of a game program
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
JP2009518433A (ja) * 2005-12-09 2009-05-07 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム 神経保護用の低用量ラドスチギルの使用
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US7767843B2 (en) * 2006-03-02 2010-08-03 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
DE602006015241D1 (de) * 2006-08-17 2010-08-12 Alembic Ltd Verbessertes verfahren zur herstellung von rivastigmin
WO2008037433A1 (en) 2006-09-29 2008-04-03 Synthon B.V. Process for making aminoalkylphenyl carbamates and intermediates therefor
CA2667553A1 (en) 2006-10-27 2008-05-02 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease
EP1942100A1 (en) * 2007-01-04 2008-07-09 Krka Tovarna Zdravil, D.D., Novo Mesto Amorphous and crystalline forms of rivastigmine hydrogentartrate
CA2677241A1 (en) * 2007-02-02 2008-08-14 Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase
EP1980552A3 (en) 2007-04-10 2008-10-29 Dr. Reddy's Laboratories Ltd. A process for the preparation of rivastigmine or a salt thereof
CN101707952B (zh) * 2007-04-16 2012-08-29 上海特化医药科技有限公司 一种制备利伐斯的明的方法及其中间体
US7884121B2 (en) * 2007-06-11 2011-02-08 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
AU2008276459A1 (en) * 2007-07-18 2009-01-22 Colucid Pharmaceuticals, Inc. Methods for promoting wakefulness
US8593728B2 (en) * 2009-02-19 2013-11-26 Toyota Motor Engineering & Manufacturing North America, Inc. Multilayer photonic structures
US20090082436A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched rivastigmine
US8324429B2 (en) * 2008-01-10 2012-12-04 Shanghai Institute Of Pharmaceutical Industry Preparation method of rivastigmine, its intermediates and preparation method of the intermediates
EP2349976B1 (en) 2008-08-25 2012-12-26 Jubilant Life Sciences Limited A process for producing (s)-3-[(1-dimethylamino)ethyl]phenyl-n-ethyl-n-methyl-carbamate via novel intermediates
US20100087768A1 (en) * 2008-10-02 2010-04-08 Forlano Paula Transdermal drug delivery system for liquid active ingredient
GB0823554D0 (en) * 2008-12-24 2009-01-28 Novartis Ag Process for the preparation of optically active compounds using transfer hydrogenation
CN101823970B (zh) * 2009-03-03 2013-05-08 江苏恩华药业股份有限公司 卡巴拉汀及其中间体的合成方法
WO2011076621A2 (de) 2009-12-22 2011-06-30 Acino Ag Transdermales therapeutisches system zur verabreichung von rivastigmin oder dessen derivaten
US10076502B2 (en) 2009-12-22 2018-09-18 Luye Pharma Ag Transdermal therapeutic system for administering rivastigmine or derivatives thereof
ES2363395B1 (es) * 2010-01-20 2012-02-23 Farmalider, S.A. Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
CN102905532A (zh) 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
BR112012024708A2 (pt) 2010-03-29 2016-06-07 Novartis Ag composição de compostos orgânicos
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2011151669A1 (en) 2010-06-02 2011-12-08 Jubilant Life Sciences Limited Process for producing enantiomerically enriched isomer of 3-(1-aminoethyl) phenyl derivative and employing the same to produce rivastigmine or its pharmaceutically acceptable salt
EP2582799B1 (en) 2010-06-17 2017-12-20 Codexis, Inc. Biocatalysts and methods for the synthesis of (s)-3-(1-aminoethyl)-phenol
EP2640391B1 (en) 2010-11-15 2015-11-11 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
SI2468274T1 (sl) 2010-12-14 2015-10-30 Acino Ag Transdermalni terapevtski sistem za dajanje aktivne snovi
CN102786441B (zh) * 2011-05-18 2013-11-13 浙江海正药业股份有限公司 利凡斯的明的制备方法、其中间体以及中间体的制备方法
EP2711002A4 (en) 2011-05-20 2014-10-29 Sk Chemicals Co Ltd PLASTER WITH RIVASTIGMIN
AR082640A1 (es) * 2011-08-25 2012-12-19 Amarin Technologies S A Un dispositivo para la administracion transdermal de compuestos alcalinos susceptibles a la degradacion en su forma no salificada
US9333182B2 (en) 2011-08-31 2016-05-10 Sekisui Medical Co., Ltd. Adhesive patch
CN103073456B (zh) * 2011-10-26 2014-03-19 连云港润众制药有限公司 重酒石酸卡巴拉汀中间体的制备方法
EP2594261A1 (en) 2011-11-18 2013-05-22 Labtec GmbH Composition for transdermal administration of rivastigmine
WO2013142339A1 (en) 2012-03-23 2013-09-26 Novartis Ag Transdermal therapeutic system and method
ES2449215B1 (es) * 2012-09-17 2014-07-14 Galenicum Health S.L. Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
KR20140038237A (ko) 2012-09-20 2014-03-28 에스케이케미칼주식회사 리바스티그민의 안정성이 개선된 의약품
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CN103896787A (zh) * 2012-12-26 2014-07-02 江苏康倍得药业有限公司 一种卡巴拉汀前体[1-(3-甲氧基苯基)乙基]二甲胺的制备方法
WO2014111790A2 (en) 2013-01-15 2014-07-24 Zydus Technologies Limited Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
DK2968220T3 (da) 2013-03-15 2021-06-14 Agenebio Inc Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
CN103319374B (zh) * 2013-06-09 2015-04-22 无锡佰翱得生物科学有限公司 一种(s)-卡巴拉汀的不对称合成方法
US10357486B2 (en) 2013-08-16 2019-07-23 Universiteit Maastricht Treatment of cognitive impairment with PDE4 inhibitor
EP4032889A1 (en) 2013-12-20 2022-07-27 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112017025031B1 (pt) 2015-05-22 2023-03-21 Agenebio, Inc Composições farmacêuticas de liberação prolongada de levetiracetam
MX392119B (es) 2015-06-19 2025-03-11 Agenebio Inc Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
IL279530B1 (en) 2018-06-19 2025-09-01 Agenebio Inc Benzodiazepine history, preparations, and methods for treating cognitive disorder
KR20200035359A (ko) 2018-09-26 2020-04-03 캐딜라 파마슈티클즈 리미티드 리바스티그민 제조용 중간체의 합성
JP2025529834A (ja) 2022-08-19 2025-09-09 エージンバイオ， インコーポレイテッド 認知障害を処置するためのベンゾアゼピン誘導体、組成物および方法
WO2025038382A1 (en) 2023-08-11 2025-02-20 Momentive Performance Materials Inc. Pharmaceutical adhesive compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469700A (en) * 1981-06-19 1984-09-04 Lowell M. Somers Benzoylecgonine or benzoylnorecgonine as active agents for the treatment of rheumatoid arthritis
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
HU201906B (en) * 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
IE61714B1 (en) 1994-11-30
US5602176A (en) 1997-02-11
DK112588D0 (da) 1988-03-02
GB8804888D0 (en) 1988-03-30
NL195004C (nl) 2003-11-04
AU1255488A (en) 1988-09-08
HU201906B (en) 1991-01-28
KR0133686B1 (ko) 1998-04-21
ATA55188A (de) 1991-08-15
IL85609A (en) 1992-07-15
FI89165B (fi) 1993-05-14
GB2203040B (en) 1990-10-24
LU87150A1 (fr) 1988-11-17
FI880972A0 (fi) 1988-03-02
KR880011088A (ko) 1988-10-26
FR2611707A1 (fr) 1988-09-09
SE8800731L (sv) 1988-09-05
SE8800731D0 (sv) 1988-03-02
BE1001467A3 (fr) 1989-11-07
MY103225A (en) 1993-05-29
CA1307003C (en) 1992-09-01
DK175762B1 (da) 2005-02-14
FR2611707B1 (fr) 1990-04-20
GB2203040A (en) 1988-10-12
NL8800436A (nl) 1988-10-03
NZ223714A (en) 1994-05-26
PT86875A (pt) 1988-04-01
CY1735A (en) 1994-06-03
JPH09165362A (ja) 1997-06-24
SE8800731A0 (sv) 1988-09-05
PT86875B (pt) 1992-05-29
HUT49325A (en) 1989-09-28
ZA881584B (en) 1989-11-29
NL195004B (nl) 2003-07-01
DK112588A (da) 1988-09-05
GR880100125A (en) 1989-01-31
IT8847693A0 (it) 1988-03-04
JPS63238054A (ja) 1988-10-04
IT1219853B (it) 1990-05-24
IE880583L (en) 1988-09-04
LU90297I2 (fr) 1998-12-07
JP2625478B2 (ja) 1997-07-02
FI880972L (fi) 1988-09-05
IL85609A0 (en) 1988-08-31
ES2010527A6 (es) 1989-11-16
AU618949B2 (en) 1992-01-16
GR1000023B (el) 1990-01-31
CH675720A5 (cs) 1990-10-31
JPH09118617A (ja) 1997-05-06
CS411091A3 (en) 1992-12-16
AT394190B (de) 1992-02-10
SA93140384B1 (ar) 2006-04-04
JP2859225B2 (ja) 1999-02-17
FI89165C (fi) 1993-08-25
GB2203040C (en) 2014-07-30

Similar Documents

Publication Publication Date Title
HK110093A (en) Phenyl carbamate
NL300084I1 (nl) Nieuwe thiofeencarbonzuur-esters van aminoalkoholen, hun kwaternairiseringsprodukten, alsmede de bereiding en toepassing van deze verbindingen.
EP0300189A3 (en) New amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
MY105121A (en) Pharmaceutical composition for systemic transdermal administration.
IT8921118A0 (it) Composizione per aerosol comprendente nitroglicerina come ingrediente attivo.
AU2348988A (en) 4H-1-benzopyran-4-one derivative or its salt, processes for producing the same and pharmaceutical composition comprising the same as active ingredient
AU7227587A (en) Substituted benzamide derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same
JPS5538382A (en) Amino acid derivative as antihypertensive drug
AU4936890A (en) Medicament containing dihydrolipoic acid as active substance
EP0160501A3 (en) Sustained release intranasal formulation and method of use thereof
IL95052A0 (en) Phosphonic acid derivatives,processes for the preparation thereof,and pharmaceutical compositions containing the same
HUT50334A (en) Process for producing arylpiperazinyl-alkilenephenyl-p-heterocycluc compounds, pharmaceutically acceptable acid addition salts thereof and pharmaceutical compositions comprising the compounds as active ingredient
IE45651L (en) Pyrrolobenzoxazaalkane derivatives
IT8722501A0 (it) Formulazioni farmaceutiche per somministrazione transdermica.
IT8722264A0 (it) Procedimento per la preparazione di compresse solubili e/o divisibili e compresse cosi' ottenute.
DK513188A (da) Aminosyreestre, deres fremstilling og anvendelse som laegemidler
FI956025A7 (fi) Menetelmä oksatsolidiinikarboksyylihapon valmistamiseksi, joka on hyödyllinen valmistettaessa terapeuttisesti vaikuttavia taksoideja
CA2182812A1 (en) Pharmaceutical composition for systemic transdermal administration containing the active agent morphine-6-glucuronide
ES2032476T3 (es) Un procedimiento para preparar nuevos derivados de 2-anilinotiazolina.
DE3864841D1 (de) Carbonsaeure-derivate.
IE810311L (en) Guanylamidines.
NO863005D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,4,5,6,7,8-heksahydro-2-alkyl-4-aryl-5-okso-1,7-naftyridin-3-karboksylsyreesterderivater.
ZA884087B (en) New amino acid derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
AU1447388A (en) Cholesteryl-phosphoryl choline as pharmaceutically active substances
HUT45854A (en) Selective fungicides comprising asymmetrical 2-pyridyl-phosphoric acid esters as active ingredient

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20080229